Clinical Study of Chinese Herbal Compound Qidan Xiaoke Granules in Patients After Coronary Revascularization
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 164 participants.
Also called NCT07616544
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 164 participants
- Sponsor
- Liu Qiang
- Registry
-
NCT07616544
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07616544. Randomized; triple masking; primary purpose treatment. Start 2026-07-01 (anticipated); primary completion 2028-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Study of Chinese Herbal Compound Qidan Xiaoke Granules in Patients After Coronary Revascularization
- Condition
- Percutaneous Coronary Intervention
- Condition
- Myocardial Revascularization
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Qidan Xiaoke Granules + Standard Medical Therapy
- Intervention (Drug)
- Placebo + Standard Medical Therapy
- Lead sponsor
- Liu Qiang
Record details
- Record id
cardio:ct-nct07616544- Content hash
447f78e5557a643584188324e6dc1071acc60901bd846b2314d05c3c1d0f73a3